Structure-Based Design and Synthesis of Benzothiazole Phosphonate Analogues with Inhibitors of Human ABAD-Aβ for Treatment of Alzheimer's Disease

Amyloid binding alcohol dehydrogenase, a mitochondrial protein, is a cofactor facilitating amyloid‐β peptide (Aß) induced cell stress. Antagonizing Aß‐ABAD interaction protects against aberrant mitochondrial and neuronal function and improves learning memory in the Alzheimer’s disease mouse model. Therefore, it offers a potential target for Alzheimer’s drug design, by identifying potential inhibitors of Aβ‐ABAD interaction. 2D QSAR methods were applied to novel compounds with known IC50 values, which formed a training set. A correlation analysis was carried out comparing the statistics of the measured IC50 with predicted values. These selectivity‐determining descriptors were interpreted graphically in terms of principle component analyses, which are highly informative for the lead optimization process with respect to activity enhancement. A 3D pharmacophore model also was created. The 2D QSAR and 3D pharmacophore models will assist in high‐throughput screening. In addition, ADME descriptors were also determined to study their pharmacokinetic properties. Finally, amyloid binding alcohol dehydrogenase molecular docking study of these novel molecules was undertaken to determine whether these compounds exhibit significant binding affinity with the binding site. We have synthesized only the compounds that have shown the best drug‐like properties as candidates for further studies. Structure‐based screening has been used to identify the inhibitors of human ABAD‐Aβ interaction, protects against aberrant mitochondrial and neuronal function and improves learning memory in the Alzheimer’s disease (AD) mouse model. The 2D QSAR and 3D pharmacophore models will assist in hi‐throughput screening. Finally, ABAD molecular docking study of these novel molecules is undertaken to determine whether these compounds exhibit significant binding affinity with the binding site.